See more : Resideo Technologies, Inc. (REZI) Income Statement Analysis – Financial Results
Complete financial analysis of APT Medical Inc. (688617.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of APT Medical Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Zhejiang Shuanghuan Driveline Co., Ltd. (002472.SZ) Income Statement Analysis – Financial Results
- Koan Hao Technology Co., Ltd. (8354.TWO) Income Statement Analysis – Financial Results
- J.G.CHEMICALS LTD (JGCHEM.NS) Income Statement Analysis – Financial Results
- Vantage Drilling International (VTDRF) Income Statement Analysis – Financial Results
- Huisen Household International Group Limited (2127.HK) Income Statement Analysis – Financial Results
APT Medical Inc. (688617.SS)
About APT Medical Inc.
APT Medical Inc. engages in the research and development, manufacture, and sale of invasive interventional medical devices for cardiovascular and cerebrovascular diseases worldwide. The company offers electrophysiological catheter delivery systems, as well as radiofrequency ablation and mapping catheters; and vascular intervention products, such as diagnostic and treatment products, and intervention accessories. It also provides OEM/ODM services to catheter and metal products, as well as accessories. The company was founded in 2002 and is headquartered in Shenzhen, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.65B | 1.22B | 828.69M | 479.44M | 403.96M | 241.77M | 153.17M |
| Cost of Revenue | 486.14M | 350.17M | 252.84M | 142.13M | 117.89M | 75.48M | 47.77M |
| Gross Profit | 1.16B | 865.85M | 575.84M | 337.31M | 286.07M | 166.29M | 105.41M |
| Gross Profit Ratio | 70.54% | 71.20% | 69.49% | 70.36% | 70.82% | 68.78% | 68.81% |
| Research & Development | 237.92M | 174.88M | 134.88M | 71.90M | 70.42M | 53.38M | 49.98M |
| General & Administrative | 13.96M | 66.55M | 19.25M | 12.38M | 11.27M | 8.05M | 7.10M |
| Selling & Marketing | 145.14M | 241.03M | 196.31M | 113.76M | 88.97M | 70.49M | 25.34M |
| SG&A | 159.10M | 307.57M | 215.56M | 126.14M | 100.24M | 78.54M | 32.45M |
| Other Expenses | 166.64M | -5.35M | 24.76M | 16.23M | 19.47M | -389.39K | -125.33K |
| Operating Expenses | 563.66M | 477.11M | 375.19M | 214.27M | 190.13M | 143.65M | 89.63M |
| Cost & Expenses | 1.05B | 827.27M | 628.04M | 356.40M | 308.02M | 219.13M | 137.40M |
| Interest Income | 4.61M | 3.19M | 2.16M | 1.21M | 684.85K | 253.48K | 1.04M |
| Interest Expense | 3.69M | 1.45M | 1.63M | 830.97K | 257.57K | 268.26K | 461.19K |
| Depreciation & Amortization | 67.89M | 51.48M | 34.54M | 20.75M | 15.33M | 9.70M | 8.06M |
| EBITDA | 672.40M | 453.02M | 256.21M | 143.22M | 106.29M | 35.47M | 39.58M |
| EBITDA Ratio | 40.75% | 37.83% | 29.59% | 30.32% | 27.00% | 13.43% | 27.25% |
| Operating Income | 600.41M | 396.99M | 222.50M | 119.45M | 92.09M | 23.60M | 31.12M |
| Operating Income Ratio | 36.38% | 32.65% | 26.85% | 24.91% | 22.80% | 9.76% | 20.32% |
| Total Other Income/Expenses | -4.05M | -1.86M | -948.86K | 1.77M | -738.46K | -389.39K | -125.33K |
| Income Before Tax | 596.37M | 395.13M | 221.55M | 121.21M | 91.36M | 23.21M | 30.99M |
| Income Before Tax Ratio | 36.14% | 32.49% | 26.74% | 25.28% | 22.61% | 9.60% | 20.23% |
| Income Tax Expense | 74.24M | 54.98M | 26.70M | 17.02M | 13.28M | 6.54M | 3.91M |
| Net Income | 533.92M | 358.02M | 207.92M | 110.78M | 82.57M | 21.51M | 34.48M |
| Net Income Ratio | 32.35% | 29.44% | 25.09% | 23.11% | 20.44% | 8.90% | 22.51% |
| EPS | 5.54 | 5.37 | 3.12 | 1.66 | 1.24 | 0.43 | 0.69 |
| EPS Diluted | 5.46 | 5.37 | 3.12 | 1.66 | 1.24 | 0.43 | 0.69 |
| Weighted Avg Shares Out | 96.29M | 66.67M | 66.67M | 66.67M | 66.67M | 50.03M | 49.97M |
| Weighted Avg Shares Out (Dil) | 97.75M | 66.67M | 66.67M | 66.67M | 66.67M | 50.03M | 49.97M |
Source: https://incomestatements.info
Category: Stock Reports